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Abstract 
Background: Pre‑evaluation of endogenous immunoglobulin levels is a potential strategy to improve the results of 
intravenous immunoglobulins in sepsis, but more work has to be done to identify those patients who could benefit 
the most from this treatment. The objective of this study was to evaluate the impact of endogenous immunoglobu‑
lins on the mortality risk in sepsis depending on disease severity.
Methods: This was a retrospective observational study including 278 patients admitted to the ICU with sepsis fulfill‑
ing the SEPSIS‑3 criteria, coming from the Spanish GRECIA and ABISS‑EDUSEPSIS cohorts. Patients were distributed 
into two groups depending on their Sequential Organ Failure Assessment score at ICU admission (SOFA < 8, n = 122 
and SOFA ≥ 8, n = 156), and the association between immunoglobulin levels at ICU admission with mortality was 
studied in each group by Kaplan–Meier and multivariate logistic regression analysis.
Results: ICU/hospital mortality in the SOFA < 8 group was 14.8/23.0%, compared to 30.1/35.3% in the SOFA ≥ 8 
group. In the group with SOFA < 8, the simultaneous presence of total IgG < 407 mg/dl, IgM < 43 mg/dl and 
IgA < 219 mg/dl was associated with a reduction in the survival mean time of 6.6 days in the first 28 days and was a 
robust predictor of mortality risk either during the acute or during the post‑acute phase of the disease (OR for ICU 
mortality: 13.79; OR for hospital mortality: 7.98). This predictive ability remained in the absence of prior immunosup‑
pression (OR for ICU mortality: 17.53; OR for hospital mortality: 5.63). Total IgG < 407 mg/dl or IgG1 < 332 mg/dl was 
also an independent predictor of ICU mortality in this group. In contrast, in the SOFA ≥ 8 group, we found no immu‑
noglobulin thresholds associated with neither ICU nor hospital mortality.
Conclusions: Endogenous immunoglobulin levels may have a different impact on the mortality risk of sepsis 
patients based on their severity. In patients with moderate organ failure, the simultaneous presence of low levels of 
IgG, IgA and IgM was a consistent predictor of both acute and post‑acute mortalities.
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Background
Pre-evaluation of endogenous immunoglobulin levels 
has been proposed as a potential tool to identify sepsis 
patients deserving replacement treatment with intra-
venous immunoglobulins (IVIG), to improve its results 
in this severe condition [1]. Nonetheless, the impact of 
endogenous immunoglobulins levels on the risk of mor-
tality in sepsis remains a controversial issue. A recent 
meta-analysis leaded by Shankar-Hari M found that the 
prevalence of IgG hypogammaglobulinemia on the day 
of sepsis diagnosis is as high as 70%, but this finding did 
not identify a subgroup of patients with a higher risk of 
death [2]. Recently, results from the SBITs (Score-based 
immunoglobulin G therapy of patients with sepsis) study 
showed that initial low IgG levels did not discriminate 
between survival and non-survival in patients with severe 
sepsis and septic shock [3]. In addition, patients with the 
highest IgG levels (fourth quartile) showed a statistically 
significant higher mortality in a risk-adjusted calculation 
compared to the reference quartile [3]. A previous report 
from our group supported that the answer could be in 
considering immunoglobulin isotypes not as isolated 
entities but in evaluating their prognostic ability in com-
bination [4, 5].
There are a number of factors that in our opinion have 
not been appropriately addressed in the studies evalu-
ating the predictive ability of immunoglobulins: (1) we 
have demonstrated in a recent article that disease sever-
ity strongly influences biomarker performance in sepsis 
[6]; (2) the influence of previous immunosuppression 
has not been evaluated [5]; (3) the impact of immuno-
globulins on hospital mortality has not been sufficiently 
studied, with the majority of works being focused on the 
acute period of the disease [2]; (4) finally, the ability of 
endogenous immunoglobulin levels to predict mortality 
in patients fulfilling the SEPSIS-3 criteria [7, 8] has not 
been reported to the present moment.
Aimed by the need of identifying patient subsets that 
could benefit the most from IVIG therapy, we have now 
evaluated the ability of endogenous immunoglobulins 
levels and also of a combined immunoglobulin score to 
predict mortality risk of sepsis patients fulfilling the SEP-
SIS-3 diagnostic criteria in two different scenarios of 
disease severity, at the short and the long term, with and 
without presence of previous immunosuppression.
Methods
Study design
Patients from two multicenter epidemiological stud-
ies on sepsis were merged to evaluate, in a retrospective 
manner, the association between levels of endogenous 
immunoglobulins in plasma and mortality depending 
on disease severity at ICU admission. One hundred and 
eighty patients came from the GRECIA study [9] (Grupo 
de Estudios y Análisis en Cuidados Intensivos), and 98 
came from the ABISS-Edusepsis study (AntiBiotic Inter-
vention in Severe Sepsis) [10]. In both studies, patients 
had sepsis at the time of admission to the ICU. For this 
study, only those patients fulfilling the new definition 
proposed by the SEPSIS-3 Consensus were considered 
[7]. Patients with human immunodeficiency virus (HIV) 
infection and those undergoing radiotherapy or receiving 
immunosuppressive drugs, including chemotherapy or 
systemic steroids, in the last 3 months prior to admission 
to the ICU were considered to be immunosuppressed. 
Exclusion criteria were cardiac arrest, therapeutic effort 
limitation and lack of informed consent. A common data 
sheet was developed to collect the clinical data, including 
medical history, physical examination and hematological, 
biochemical, radiological and microbiological investiga-
tions from the two studies. Treatment decisions were not 
standardized for all patients but were made by the treat-
ing physician, always based upon the Surviving Sepsis 
Campaign guidelines recommendations.
Immunoglobulin quantification
A 5-ml sample of blood was collected in an EDTA tube 
from all patients in the first 12  h following ICU admis-
sion. The blood was centrifuged, and plasma was obtained 
and stored at −80 °C until required for immunoglobulin 
quantification. Plasma levels of immunoglobulins were 
measured using a multiplex immunoglobulin isotyping 
kit (Biorad TM, Hercules, CA, USA) on a Luminex plat-
form. All plasma samples from the two studies (GRECIA 
and ABISS) were tested for immunoglobulin concentra-
tions using the same equipment, to avoid potential bias 
due to multiplatform testing.
Statistical analysis
For the demographic and clinical characteristics of the 
patients, differences between groups were assessed 
using the Chi-square test for categorical variables and 
the Mann–Whitney U test for continuous variables 
when appropriate. Patients were split into two groups 
based upon the percentile 50 for the Sequential Organ 
Failure Assessment (SOFA) score at ICU admission. In 
consequence, two groups of patients were generated 
(SOFA  <  8 and SOFA ≥  8). Deciles of immunoglobulin 
concentrations were used to categorize patients below 
or above each decile, creating the corresponding cat-
egorical variables. Deciles were calculated for the entire 
cohort, since no differences for immunoglobulin levels 
were found between patients with SOFA score <8 and 
those with SOFA scores ≥8 (Table  1). We determined 
the occurrence of death in each severity group using 
Kaplan–Meier curves. Time was censored at day 28 
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following admission to the ICU for this analysis. The first 
decile showing significant differences between groups 
based on the log-rank test was considered as the immu-
noglobulin threshold. We established immunoscores 
(ISC) for identifying those patients with the combined 
presence of low levels of two or more immunoglobulins 
(below each respective threshold). An overall score of 0 
was assigned to all patients with levels below the thresh-
olds for all immunoglobulins forming each immunoscore 
and a score of 1 to the remaining patients. The dichoto-
mous variables created for each immunoglobulin using 
the identified thresholds as well as the immunoscores 
were further introduced into a multivariate logistic 
regression analysis to determine the association between 
Table 1 Clinical characteristics of the patients
Continuous variables are shown as median (inter‑quartile rank) and categorical variables as n (%)
n.s. not significant





Characteristics Cohort GRECIA/ABISS 81/41 99/57 n.s
Age (years) 70.5 (18.0) 67.50 (19.0) n.s
Sex (male) 70 (57.4%) 112 (71.8%) 0.012
Comorbidities Chronic cardiovascular disease 15 (12.3%) 21 (13.5%) n.s
Chronic respiratory disease 21 (17.2%) 29 (18.6%) n.s
Chronic renal failure 12 (9.80%) 16 (10.3%) n.s
Chronic hepatic failure 2 (1.6%) 11 (7.1%) 0.034
Diabetes mellitus 23 (18.9%) 24 (15.4%) n.s
Immunosuppression 23 (18.9%) 39 (25.0%) n.s
Severity and outcome APACHE‑II 18.0 (7.0) 23.0 (10.0) 0.001
Sepsis with cardiovascular dysfunction 77 (63.1%) 147 (94.2%) 0.001
Mortality at the ICU 18 (14.8%) 47 (30.1%) 0.003
Mortality at the hospital 28 (23.0%) 55 (35.3%) 0.026
Source of infection Respiratory 47 (40.2%) 59 (38.8%) n.s
Abdominal 38 (32.5%) 44 (29.1%) n.s
Urinary tract 14 (12.0%) 21 (13.9%) n.s
Bacteremia–catheter 3 (2.6%) 11 (7.3%) n.s
Other 15 (12.8%) 15 (9.9%) n.s
Microbiologically confirmed infection 57 (46.7%) 92 (59.0%) 0.047
Microbiology Gram‑negative bacteria 28 (23%) 55 (35.3%) 0.029
Gram‑positive bacteria 31 (25.4%) 35 (22.4%) n.s
Fungemia 6 (4.9%) 3 (1.9%) n.s
Other 4 (3.3%) 4 (2.6%) n.s
Polimicrobian sepsis 16 (13.1%) 11 (7.1%) n.s
Laboratory parameters at diagnosis White blood cells (cells/mm3) 15.800 (9500) 15.400 (15,080) n.s
Platelets/µl 210.000 (136,000) 133.000 (142,500) 0.001
Potassium (mEq/l) 4.2 (0.8) 4.3 (1.0) n.s
Sodium (mEq/l) 138.0 (8.0) 139.0 (9.0) n.s
Glycemia (mg/dl) 167.0 (94.0) 170.0 (87.0) n.s
Creatinine (mg/dl) 1.2 (1.1) 2.0 (1.7) 0.001
Albumin (g/dl) 2.3 (1.0) 2.3 (0.8) n.s
IgG total (mg/dl) 618.2 (516.0) 528.7 (469.0) n.s
IgG1 (mg/dl) 482.6 (370.5) 446.71 (377.9) n.s
IgG2 (mg/dl) 17.8 (28.2) 15.0 (21.2) n.s
IgG3 (mg/dl) 51.1 (76.0) 49.8 (62.0) n.s
IgG4 (mg/dl) 17.2 (46.5) 16.3 (35.0) n.s
IgM (mg/dl) 38.0 (37.4) 36.40 (32.1) n.s
IgA (mg/dl) 278.7 (343.0) 273.3 (375.6) n.s
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immunoglobulin levels and the risk of mortality at the 
ICU and also at the hospital. Those variables of Table 1 
yielding p values <0.1 in the univariate analysis were con-
sidered as potential confounding factors and were further 
introduced in the multivariate one as adjusting variables. 
Data analysis was performed using SPSS for WINDOWS 
version 22.0 software (IBM-SPSS, Chicago, IL, USA).
Results
Clinical characteristics of the patients depending 
on disease severity at ICU admission
 In order to evaluate the potential differences between the 
patients included in the two severity groups, a descrip-
tive table was built (Table  1). This table is important to 
find out whether or not patients’ characteristics could 
explain the different results found for the two groups 
regarding the association between immunoglobulin lev-
els and the risk of mortality, as showed later in this sec-
tion. Table 1 shows that patients were elderly individuals, 
with the group of patients with SOFA score ≥  8 having 
a significant higher proportion of men. The most fre-
quent comorbidities found in both groups of patients 
were chronic cardiovascular disease, chronic respira-
tory disease, chronic renal failure and diabetes mellitus. 
The most severe group of patients showed a significant 
higher frequency of patients with history of chronic 
hepatic failure. The proportion of patients with prior 
immunosuppression did not differ in a significant man-
ner between both groups. Sources of infection were simi-
lar in the two groups compared, with predominance of 
sepsis of respiratory, abdominal and urological origin. 
Both groups presented also a similar proportion of infec-
tions caused by Gram + bacteria and fungi, but the most 
severe group had a significant higher frequency of infec-
tions caused by Gram-negative bacteria along with an 
overall higher frequency of patients with microbiologi-
cally confirmed infection. Ninety-four percentage of the 
patients with SOFA ≥  8 presented with cardiovascular 
dysfunction, compared with 63% in the group of patients 
with SOFA < 8. As expected, patients in the most severe 
group showed higher APACHE-II scores, higher creati-
nine levels in plasma, and lower platelets counts in blood. 
In addition, mortality at the ICU and also at the hospi-
tal was markedly higher in this group. Immunoglobulin 
and albumin levels in plasma did not differ in a signifi-
cant manner between both groups of patients. In those 
patients with positive microbiological identification, 
proportion of patients receiving appropriated antibiotic 
treatment based on the antibiogram results was similar 
between both severity groups (80 vs. 73%, p = 0.420).
Fig. 1 Kaplan–Meier analysis for survival depending on immunoglobulin levels in the group with SOFA < 8
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Identification of immunoglobulin thresholds associated 
with mortality
Kaplan–Meier analysis identified five immunoglobu-
lin thresholds associated with mortality in the group of 
patients with SOFA  <  8, corresponding to IgG, IgG1, 
IgG2, IgM and IgA (Fig.  1). The triple ISC built based 
upon the thresholds corresponding to the three major 
immunoglobulin isotypes (IgG, IgM and IgA) showed 
the highest impact on survival mean time, which was 
reduced 6.6 days in average in those patients showing a 
ISC IgGAM = 0 (Fig. 1; Additional file 1). When Kaplan–
Meier analysis was repeated for those patients of the 
most severe group (those with SOFA ≥ 8), no thresholds 
associated with mortality were identified for individual 
immunoglobulins (Fig.  2). In addition, the ISC IgGAM 
failed to show any association with mortality in this anal-
ysis (Fig. 2).
Regression analysis for prediction of mortality risk
To evaluate the impact of the immunoglobulin thresh-
olds on the mortality risk over the acute phase of the 
disease and also over the post-acute phase of the disease, 
regression analysis for predicting either ICU or hospital 
mortality was performed in the group of patients with 
SOFA < 8:
ICU mortality
We first compared the proportion of survivors and non-
survivors at the ICU in the patients with immunoglobu-
lin levels below/above these thresholds (Table 2):
Those thresholds showing differences at the level 
p < 0.1 in Table 2 are further evaluated for their associa-
tion with the risk of ICU mortality by using a multivariate 
analysis (Table  3). This analysis evidenced that exhibit-
ing levels of IgG, IgG1 below their respective thresholds 
or having an ISC IgGAM =  0 was a robust, independ-
ent risk marker of ICU mortality. The highest odds ratio 
corresponded to the ISC IgGAM. While the presence of 
patients with prior immunosuppression did not affect 
the predictive ability of IgG, IgG1 and ISC IgGAM, it 
did influence IgG2, which was only able to predict mor-
tality in those patients with no previous antecedents of 
immunosuppression.
Hospital mortality
When hospital mortality was analyzed, only ISC IgGAM 
showed differences for the proportion of survivors and 
non-survivors between patients with low and high immu-
noglobulin levels (Table 4).
The multivariate analysis confirmed that the ISC 
IgGAM was a strong predictor of the risk of hospital 
Fig. 2 Kaplan–Meier analysis for survival depending on immunoglobulin levels in the group with SOFA ≥ 8
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mortality, not affected by the presence of prior immuno-
suppression (Table 5).
Multivariate regression analysis for the ISCs combining 
two immunoglobulins was not performed since the vast 
majority of non-survivors showing a “0” in the double 
ISCs showed also a “0” in the triple ISC (overlap with the 
triple score was 100% for ISC IgGM, of 90% for ISC IgGA 
and 82% for ISC IgMA).
Potential influence of hemodilution on the results
Interestingly, hemodilution had no effect on the results 
observed in the less severe group of patients, as evi-
denced by the absence of significant correlation in the 
Spearman test between levels of immunoglobulins and 
albumin concentration in plasma (p > 0.05).
Discussion
This study shows for the first time that the influence of 
endogenous immunoglobulin levels on the prognosis of 
patients with sepsis seems to be restricted to a subset of 
individuals presenting at the ICU with limited extent of 
organ failure. Our results evidenced also that the simul-
taneous presence of low levels of IgG, IgA and IgM was 
found to be a consistent predictor of both acute mortality 
(at the ICU) and post-acute mortality (at the hospital) in 
these patients, independently of the presence or absence 
of previous immunosuppression. In contrast, the ability 
of total IgG or IgG1 to predict mortality was restricted 
to the acute period of the disease (ICU mortality). While 
the presence of patients with previous immunosuppres-
sion did not alter the predictive ability of total IgG and 
Table 2 Proportion of  survivors and  non-survivors at  the ICU in  the group of  patients with  SOFA score <8 depending 
on the immunoglobulin thresholds
Thresholds SOFA < 8: ICU mortality
Patients with prior immunosuppression included 
(n = 122)
Patients with prior immunosuppression excluded 
(n = 99)
Non-survivors/total “n” in each category % p Non-survivors/Total “n” in each category % p
IgG (total) <407 mg/dl 8/31 25.8 0.045 6/24 25.0 0.048
≥407 mg/dl 10/91 14.8 7/75 9.3
IgG1 <332 mg/dl 8/30 26.7 0.034 6/24 25.0 0.048
≥332 mg/dl 10/92 14.8 7/75 9.30
IgG2 <10 mg/dl 9/39 23.1 0.076 8/32 25.0 0.016
≥10 mg/dl 9/83 10.8 5/67 7.5
IgM <43 mg/dl 13/72 18.1 0.217 9/54 16.7 0.254
≥43 mg/dl 5/50 10.0 4/45 8.9
IgA <219 mg/dl 10/49 20.4 0.149 7/39 17.9 0.253
≥219 mg/dl 8/73 11.0 6/60 10.0
ISC IgGAM =0 7/17 41.2 0.001 5/12 41.7 0.002
=1 11/105 10.5 8/87 9.2
Table 3 Multivariate logistic regression analysis to  evaluate the association between  immunoglobulins and  the risk 
of mortality at the ICU in the group of patients with SOFA score <8
Adjusting variables for A. were (diabetes mellitus) (presence of prior immunosuppression) (APACHE‑II score) (presence of respiratory infection), (microbiologically 
confirmed infection). Adjusting variables for B. were (APACHE‑II score) (presence of respiratory infection), (presence of abdominal infection) (microbiologically 
confirmed infection)
Immunoglobulins SOFA < 8
A. Patients with prior immunosuppression included 
(n = 122)
B. Patients with prior immunosuppression 
excluded (n = 99)
OR CI 95% p OR CI 95% p
IgG (total) < 407 mg/dl 7.29 1.62 32.79 0.010 9.02 1.45 56.30 0.019
IgG1 < 332 mg/dl 8.02 1.82 35.32 0.006 8.95 1.44 55.79 0.019
IgG2 < 10 mg/dl 3.71 0.93 14.80 0.064 6.22 1.08 35.72 0.040
ISC IgGAM = 0 13.79 2.61 72.98 0.002 17.53 2.23 137.57 0.006
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IgG1, it modified that of IgG2, which was only able to 
predict ICU mortality in those patients with no previous 
immunosuppression. These findings reinforce the superi-
ority of the combined immunoglobulin score over immu-
noglobulins individually considered to identify sepsis 
patients at risk of poor outcomes [4].
In the era of precision medicine in sepsis [11, 12], 
defining the immunological state of the patient will be 
crucial to the success of any biological response modi-
fier for sepsis [13, 14]. Our findings could contribute to 
personalize treatment with IVIG in this disease. Failure 
of IVIG in demonstrating clinical benefit in sepsis [15] 
could be explained by different factors concerning both 
the patient and the IVIG preparation, which have already 
been discussed elsewhere [1, 16]. Our results provide 
new clues to better design future trials with IVIG in sep-
sis and/or to improve data analysis from these trials. The 
more relevant would be that sepsis patients should not be 
considered as a homogenous population. The impact of 
IVIG on the outcome of the patients should be analyzed 
stratifying the patients by their levels of endogenous 
immunoglobulins and by the degree of disease severity at 
ICU admission. Quantification of immunoglobulin levels 
using nephelometry is a fast test which takes less than 
2 h. In turn, the SOFA score has widespread familiarity 
within the critical care community, making it useful to 
assess the degree of organ failure extent at ICU admis-
sion [7, 17]. In addition, our results provide a scientific 
rational to evaluate whether IVIG preparations contain-
ing IgG, IgA and IgM could be more effective for the 
treatment of sepsis than those containing exclusively IgG 
[18–20]. Interestingly, Kreymann KG et al., a meta-analy-
sis in 2007 of all randomized controlled studies published 
on polyvalent immunoglobulins for treatment of sepsis 
or septic shock, observed a strong protective trend in 
favor of an immunoglobulin preparation containing the 
three major immunoglobulin isotypes [21].
As a major limitation of our study, immunoglobulins 
were measured in samples already available from the 
GRECIA and the ABISS studies, and in consequence, it 
Table 4 Proportion of survivors and non-survivors at the hospital in the group of patients with SOFA score <8 depending 
on the immunoglobulin thresholds
Thresholds SOFA < 8: Hospital mortality
Patients with prior immunosuppression included 
(n = 122)
Patients with prior immunosuppression excluded 
(n = 99)
Non-survivors/Total “n” in each category % p Non-survivors/Total “n” in each category % p
IgG (total) <407 mg/dl 10/31 32.3 0.119 7/24 29.2 0.209
≥407 mg/dl 18/91 19.8 13/75 17.3
IgG1 <332 mg/dl 10/30 33.3 0.119 7/24 29.2 0.209
≥332 mg/dl 18/92 19.6 13/75 17.3
IgG2 <10 mg/dl 11/39 28.2 0.344 9/32 28.1 0.175
≥10 mg/dl 17/83 20.5 11/67 16.4
IgM <43 mg/dl 19/72 26.4 0.279 12/54 22.2 0.583
≥43 mg/dl 9/50 18.0 8/45 17.8
IgA <219 mg/dl 14/49 28.6 0.226 10/39 25.6 0.277
≥219 mg/dl 14/73 19.2 10/60 16.7
ISC IgGAM =0 9/17 52.9 0.002 6/12 50.0 0.006
=1 19/105 18.1 14/87 16.1
Table 5 Multivariate logistic regression analysis to  evaluate the association between  immunoglobulins and  the risk 
of mortality at the hospital in the group of patients with SOFA score <8
Adjusting variables for A. were (age) (presence of prior immunosuppression) (APACHE‑II score) (microbiologically confirmed infection). Adjusting variables for B were 
(APACHE‑II score) (respiratory infection) (microbiologically confirmed infection)
Immunoglobulins SOFA < 8
A. Patients with prior immunosuppression included 
(n = 122)
B. Patients with prior immunosuppression 
excluded (n = 99)
OR CI 95% p OR CI 95% p
ISC IgGAM = 0 7.98 1.94 32.87 0.004 5.63 1.13 28.11 0.035
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was retrospective in nature. This makes that sample size 
was not calculated based on a predefined primary out-
come, which may represent a source of bias. Another 
limitation was the absence of lactate registries in many 
patients, which precluded identifying those patients ful-
filling the new definition of septic shock as proposed by 
the SEPSIS-3 consensus [8]. In consequence, new pro-
spective studies should confirm the results obtained in 
this work.
Conclusions
Results from this study suggest that endogenous immu-
noglobulin levels may have a different impact on the 
mortality risk of sepsis patients based on their severity. 
Future studies should be directed to investigate whether 
IVIG therapy may particularly benefit subsets of patients 
with moderate organ failure extent and low levels of the 
three immunoglobulin isotypes.
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